Thinly traded micro cap Arcturus Therapeutics (NASDAQ:ARCT) is up 12% premarket on light volume in reaction to positive immunogenicity data from a preclinical study of its COVID-19 vaccine candidate LUNAR-COV19.
According to CSO Pad Chivukula, Ph.D., the
company’s STARR mRNA is superior to conventional mRNA at equivalent
doses and time points, adding that self-replicating mRNA “significantly”
increases spike protein expression, yielding “many-fold” higher
seroconversion rates suggesting that the 2 µg dose could potentially
immunize millions more people.
https://seekingalpha.com/news/3564593-arcturus-up-12-premarket-on-promising-covidminus-19-vaccine-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.